BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang J, Yu YL, Jin Y, Zhang Y, Zheng CQ. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World J Gastroenterol 2016; 22(33): 7579-7586 [PMID: 27672278 DOI: 10.3748/wjg.v22.i33.7579]
URL: https://www.wjgnet.com/1007-9327/full/v22/i33/7579.htm
Number Citing Articles
1
Rolf Teschke, Gaby Danan. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method UseInternational Journal of Molecular Sciences 2023; 24(13): 10855 doi: 10.3390/ijms241310855
2
Melissa Palmer, Arie Regev, Keith Lindor, Mark I. Avigan, Lara Dimick‐Santos, William Treem, John F. Marcinak, James H. Lewis, Frank A. Anania, Daniel Seekins, Benjamin L. Shneider, Naga Chalasani. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury occurring during clinical trials in adults with chronic cholestatic liver diseaseAlimentary Pharmacology & Therapeutics 2020; 51(1): 90 doi: 10.1111/apt.15579
3
Shizuka Okazaki, Toshihiko Hoashi, Hidehisa Saeki, Naoko Kanda. A Case of Autoimmune Hepatitis/Primary Biliary Cholangitis Overlap Syndrome during Treatment with Brodalumab for Generalized Pustular PsoriasisJournal of Nippon Medical School 2021; 88(6): 569 doi: 10.1272/jnms.JNMS.2021_88-517
4
Wen Li, Fang Yuan, Lai-You Wang. Mechanism, prevention, and treatment of drug-induced cholestasisWorld Chinese Journal of Digestology 2019; 27(21): 1295 doi: 10.11569/wcjd.v27.i21.1295
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
5
Guoxin Xu, Yanping Gong, Fenying Lu, Bin Wang, Zaixing Yang, Long Chen, Jingyu Min, Cuie Cheng, Tingwang Jiang. Endothelin receptor B enhances liver injury and pro-inflammatory responses by increasing G-protein-coupled receptor kinase-2 expression in primary biliary cholangitisScientific Reports 2022; 12(1) doi: 10.1038/s41598-022-21816-x
6
Weijia Duan, Sha Chen, Shuxiang Li, Tingting Lv, Buer Li, Xiaoming Wang, Yu Wang, Xinyan Zhao, Hong Ma, Xiaojuan Ou, Hong You, Jidong Jia. The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti‐mitochondrial antibodies but without baseline PBCHepatology Communications 2022; 6(11): 3112 doi: 10.1002/hep4.2067
7
Xin Yu, Ying Chen, Lele Cui, Kaming Yang, Xumeng Wang, Linyuan Lei, Yanping Zhang, Xinyi Kong, Wanwen Lao, Zhenlin Li, Yang Liu, Yuetong Li, Changlong Bi, Chao Wu, Aixia Zhai. CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis BFrontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.1052917
8
Rolf Teschke, Gaby Danan. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive AnalysisMedicines 2020; 7(10): 62 doi: 10.3390/medicines7100062
9
Sabine Weber, Andreas Benesic, Marie-Luise Buchholtz, Isabelle Rotter, Alexander L. Gerbes. Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver InjuryDigestive Diseases 2021; 39(3): 275 doi: 10.1159/000511635
10
Qingling Xu, Weijia Zhu, Yufeng Yin. Diagnostic value of anti-mitochondrial antibody in patients with primary biliary cholangitis: A systemic review and meta-analysisMedicine 2023; 102(45): e36039 doi: 10.1097/MD.0000000000036039
11
Ma Xiaohan, Yang Lixia, Zeng Xiangyu, Liu Wanting. Comparison of Clinical and Pathologic Features of Antimitochondrial Antibodies-negative Primary Biliary Cirrhosis and Cholestatic Type Drug-induced Liver InjuryJournal of Clinical Gastroenterology 2024;  doi: 10.1097/MCG.0000000000002126
12
Rolf Teschke. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00730
13
S. Zandanell, M. Strasser, A. Feldman, J. Tevini, G. Strebinger, D. Niederseer, G. Pohla‐Gubo, U. Huber‐Schönauer, S. Ruhaltinger, B. Paulweber, C. Datz, T.K. Felder, E. Aigner. Low rate of new‐onset primary biliary cholangitis in a cohort of anti‐mitochondrial antibody‐positive subjects over six years of follow‐upJournal of Internal Medicine 2020; 287(4): 395 doi: 10.1111/joim.13005